Source: MrrTrack model
Estimated active users × assumed paying share × estimated monthly revenue per customer. We distinguish B2B, B2C and creator tools, and use comparable revenue when available. These are model assumptions, not measured sales.
Indicative range $53–$3.8k
Share of monthly visits
Map unavailable. Country shares are listed alongside.
Select a country to locate it
We're hiring world-class talent for data scientist jobs, software engineers, and front-end developer roles. Work remotely!
Share of monthly visits
Updated: 09/01/2026
Share calculated from Meta's reported reach breakdown. Spend by country is not published.
Traffic, revenue and acquisition: the data behind the product.
Catalog updated on
We're hiring world-class talent for data scientist jobs, software engineers, and front-end developer roles. Work remotely!
Official website appsilon.comAccelerate Drug Development with AI and Open Source receives an estimated 38,137 visits in September 2026.
This represents a change of -8.1% compared with August 2026 (41,487 visits).
These are estimated visits, not unique users or paying customers. Traffic growth does not establish sales growth.
| Month | Visits |
|---|---|
| 50,992 | |
| 41,487 | |
| 38,137 |
Accelerate Drug Development with AI and Open Source has an estimated monthly revenue of $450. This is an estimate, not company-reported revenue or payment-verified MRR.The model uses available product, traffic and comparable SaaS signals; its assumptions remain uncertain.
The leading countries for visits to Accelerate Drug Development with AI and Open Source are: United States (16.5%), Norway (13.3%), Australia (8.8%). These shares describe website traffic, not the location of paying customers.
The recorded channels include: Direct (41.4%), Referrals (11.1%), Email (2.8%).Coverage may be partial: a missing value does not establish that a channel is unused. These visits do not measure conversions or advertising returns.
The YouTube and Meta Ads sections let you explore collected mentions and creatives. Access depends on your account and subscription.
Explore acquisition dataThe selection of SaaS to compare includes Playroll, Revelo, Fetcher, Big.jobs.Similarity is assessed from available descriptions, categories and use cases. It does not guarantee equivalent features or pricing.
Answers based on the data available in this profile.
Accelerate Drug Development with AI and Open Source receives an estimated 38,137 visits in September 2026. These are estimated visits, not unique users or paying customers. Traffic growth does not establish sales growth.
Accelerate Drug Development with AI and Open Source has an estimated monthly revenue of $450. This is an estimate, not company-reported revenue or payment-verified MRR.The model uses available product, traffic and comparable SaaS signals; its assumptions remain uncertain.
This represents a change of -8.1% compared with August 2026 (41,487 visits). These are estimated visits, not unique users or paying customers. Traffic growth does not establish sales growth.
The leading countries for visits to Accelerate Drug Development with AI and Open Source are: United States (16.5%), Norway (13.3%), Australia (8.8%). These shares describe website traffic, not the location of paying customers.
The selection of SaaS to compare includes Playroll, Revelo, Fetcher, Big.jobs.Similarity is assessed from available descriptions, categories and use cases. It does not guarantee equivalent features or pricing.
The catalog data was last updated on October 17, 2026.The latest available traffic month is September 2026.Traffic periods, collection dates and revenue source dates can differ.